1 Correction to: Clin Drug Investig (2018) 38:239–247 https://doi.org/10.1007/s40261-017-0606-0

The original version of this article unfortunately contained a mistake. The correct information is given below.


Page 242, Section 3.3, 1st paragraph, which previously read:


Baseline virologic resistance was assessed in all patients, except for one patient with HCV mono-infection who had other virologic outcome (n = 124). NS5A was successfully deep-sequenced in all 124 patients. At baseline, 2% (3/124) of patients had NS5A RASs using a 15% assay cut-off; one genotype 1b-infected patient had the L31M RAS, and two genotype 1b-infected patients had the Y93H RAS. NS5B was successfully deep-sequenced in 123 patients; NS5B amplification failed in one patient co-infected with genotype 1 HCV and HIV. Thirty-four genotype 1b-infected patients had L159F NS5B NI RAS present at baseline using a 15% assay cut-off. All patients with baseline RASs achieved SVR12. None of the patients who relapsed had any RASs at baseline or time of virologic failure.


Should read:


Baseline virologic resistance was assessed in all patients, except for one patient with HCV mono-infection who had other virologic outcome (n = 125). NS5A was successfully deep-sequenced in all 125 patients. At baseline, 3% (4/125) of patients had NS5A RASs using a 15% assay cut-off; one genotype 1b-infected patient had the L31M RAS, and three genotype 1b-infected patients had the Y93H RAS. NS5B was successfully deep-sequenced in 124 patients; NS5B amplification failed in one patient co-infected with genotype 1 HCV and HIV. Thirty-five genotype 1b-infected patients had L159F NS5B NI RAS present at baseline using a 15% assay cut-off. All patients with baseline RASs achieved SVR12. None of the patients who relapsed had any RASs at baseline or time of virologic failure.